Liquid Biopsy Enabling Precision Oncology Clinical Trials

  • Defining ctDNA guided clinical trial designs and assay performance requirements for each
  • Showcasing ctDNA as a key secondary endpoint of th e TRIDENT-1 clinical trial, a case study discussion
  • Partnering on the development of a WGS MRD distributed kit